Skip to main content
Photo of  Bryan C. Hambley, MD, MPH

Bryan C. Hambley, MD, MPH

Assistant Professor of Clinical

Internal Medicine | College of Medicine

  • Bachelor's Degree: University of Notre Dame
  • Master's Degree: Tulane University School of Public Health
  • Medical Degree: Tulane University School of Medicine
  • Internship: Case Western Reserve University
  • Chief Resident: Case Western Reserve University
  • Fellowship: Case Western Reserve University
  • Fellowship: Johns Hopkins Hospital
  • Fellowship: Johns Hopkins Hospital
Board Certifications & Licenses

American Board of Internal Medicine (Critical Care Medicine) (Certification Date: 20201215)
American Board of Internal Medicine (Hematology) (Certification Date: 20191025)
American Board of Internal Medicine (Certification Date: 20150811)


Critical Care Medicine
Internal Medicine

Contact Information

Clinical Interests

Critical Care Medicine

Hematology and Oncology


Acute Lymphocytic Leukemia

Acute Myeloid Leukemia


Castleman Disease

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia



M Protein


Mediastinal Adenopathy

Monoclonal gammopathy

Monoclonal protein

Mycosis Fugoides

Myelodysplastic Syndrome


Myeloproliferative Disorder


Plasma Cell Disorder

Plasminogen Activator Inhibitor 1

Polycythemia vera


Sideroblastic anemia

T-cell lymphoma



I specialize in the care of patients with blood cancers and have particular expertise in the treatment of patients with leukemia, MDS, and rare hematologic disorders (such as aplastic anemia, other bone marrow failure conditions, and HLH). Within these diseases, I am interested in the role of autologous and allogeneic stem cell transplantation, as well as cellular therapies such as CAR T-cells.

Peer Reviewed Publications

Alex Ambinder, Bryan Hambley, Satish Shanbhag, and Sam Merrill 2019. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins American Journal of Hematology, ,

Bryan Hambley, Kelly Norsworthy, Jagar Jasem, Jacquelyn Zimmerman et al. 2019. Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction Leukemia Research, ,

Eric Gehrie et al. 2019. One-unit compared to two-unit platelet transfusions for adult oncology outpatients Vox Sanguinis, ,

Bryan Hambley, Paolo Caimi, and Basem William 2016. Bortezomib for the treatment of mantle cell lymphoma: an update Therapeutic Advances in Hematology, ,